Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607692 | 0.84 | LOXL2 (0.44) | GRM2ENPP1ENPP3KCNH2 | |
| SCHEMBL2925165 | 0.81 | MAOB (0.43) | ENPP1ENPP3KCNH2 | |
| SCHEMBL2922147 | 0.81 | KCNH2 (0.35) | WNT3AENPP1ENPP3KCNH2 | |
| Hydrochloric Acid SCHEMBL2926449 | 0.81 | MAOB (0.44) | KCNH2 | |
| SCHEMBL3632623 | 0.80 | KCNH2 (0.42) | MEN1KCNH2 | |
| SCHEMBL2925641 | 0.77 | GRM2 (0.44) | GRM2 | |
| SCHEMBL15884572 | 0.76 | RAF1 (0.44) | MEN1NPC1 | |
| SCHEMBL3115300 | 0.76 | DYRK1A (0.48) | NPC1 | |
| SCHEMBL2925960 | 0.76 | AKT1 (0.42) | GRM2 | |
| SCHEMBL2919816 | 0.75 | PDE10A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | claimed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | claimed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | GRM2 4881/4885WNT3A 4383/4885SLC22A12 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.